
ARAV
Healthcare · Biotechnology · $2.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · -33.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2023 | After the close | -0.10 | 0.28 | +380.0% |
| Aug 21, 2023 | After the close | -0.29 | -0.12 | +58.6% |
| May 10, 2023 | After the close | -0.32 | -0.66 | -106.3% |
| Mar 15, 2023 | After the close | -0.30 | -0.46 | -53.3% |
| Nov 10, 2022 | After the close | -0.64 | -0.51 | +20.3% |
| Aug 11, 2022 | After the close | -0.59 | -0.61 | -3.4% |
| May 12, 2022 | Before the open | -0.53 | -0.62 | -17.0% |
| Mar 31, 2022 | After the close | -0.60 | -0.62 | -3.3% |
| Oct 28, 2021 | After the close | -0.46 | -0.53 | -15.2% |
| Aug 5, 2021 | After the close | -0.38 | -0.35 | +7.9% |
| May 6, 2021 | After the close | -0.45 | -0.44 | +2.2% |
| Mar 16, 2021 | After the close | -0.52 | -0.25 | +51.9% |
| Nov 5, 2020 | After the close | -0.42 |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase…
| -0.66 |
| -57.1% |
| Aug 3, 2020 | After the close | -0.46 | -0.32 | +30.4% |
| May 6, 2020 | After the close | -0.35 | -0.72 | -105.7% |
| Mar 27, 2020 | Before the open | -0.51 | -0.35 | +31.4% |
| Nov 7, 2019 | After the close | -0.50 | -0.54 | -8.0% |
| Aug 7, 2019 | After the close | -0.56 | -0.27 | +51.8% |
| May 8, 2019 | After the close | -0.86 | -0.42 | +51.2% |
| Mar 7, 2019 | After the close | -7.02 | -4.82 | +31.3% |
| Nov 6, 2018 | After the close | -6.36 | -1.08 | +83.0% |
| Aug 7, 2018 | After the close | -5.76 | -1.62 | +71.9% |
| May 8, 2018 | After the close | -5.16 | -1.50 | +70.9% |
| Mar 1, 2018 | After the close | -5.59 | 5.22 | +193.4% |